Stereotactic Ablative Radiotherapy Before Resection to Avoid Delay for Early-stage Lung Cancer or Oligometastases During the COVID-19 Pandemic

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Stereotactic Ablative Radiotherapy Before Resection to Avoid Delay for Early-stage Lung Cancer or Oligometastases During the COVID-19 Pandemic

header-info

May, 25, 2023

Preliminary surgical and pathological results of the SABR-BRIDGE protocol indicate that adopting stereotactic ablative radiotherapy as a bridge to surgery results in successful and well-tolerated treatment for patients with early-stage presumed or biopsy-proven lung malignancy during operating room closures.

Access the full article to read more here.